# US 2015/0031712 A1 · Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031712 A1
- Document ID: US20150031712A1
- Status: Published application
- Kind: A1
- Application number: 14/483,181
- Filed: 2014-09-11
- Published: 2015-01-29
- Earliest claimed: 2013-03-12
- Inventors: Moshe ROGOSNITZKY
- Web page: https://patentgrep.com/patent/US20150031712A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A treatment pack comprising: (a) multiple doses of a composition containing dipyridamole as an active ingredient; (b) packaging material; and (c) instructions for topical administration of said composition to the anterior segment of the eye to treat an anterior segment eye disorder.

## Claims

### Claim 1

A treatment pack comprising:
(a) multiple doses of a composition containing dipyridamole as an active ingredient;
(b) packaging material; and
(c) instructions for topical administration of said composition to the anterior segment of the eye to treat an anterior segment eye disorder.

### Claim 2 (depends on 1)

A treatment pack according to claim 1, wherein said composition is formulated in a form selected from the group consisting of solution, cream and ointment.

### Claim 3 (depends on 1)

A treatment pack according to claim 1, wherein said composition does not comprise a physiologically effective amount of any member of the group consisting of caffeine, a corticosteroid, a benzisoselenazole (e.g. ebselen), amoxapine, sertraline, dipivefrin, prostaglandin E, rolipram, an additional anti-VEGF compound, and an HMG-CoA reductase inhibitor (e.g. a statin) and/or nitric oxide (NO) inhibitors if said instructions are followed.

### Claim 4 (depends on 1)

A treatment pack according to claim 1, wherein said composition contains dipyridamole at a concentration of at least about 10−6 molar (moles/liter).

### Claim 5 (depends on 1)

A treatment pack according to claim 1, wherein said instructions specify administration of said composition to the eye(s) of a subject at least once every other day.

### Claim 6 (depends on 1)

A treatment pack according to claim 1, wherein said instructions specify a dosing regimen which leads to an aggregate daily dosage of dipyridamole of 0.5 mg per day or less.

### Claim 7 (depends on 1)

A treatment pack according to claim 1, comprising a single container for said multiple doses.

### Claim 8 (depends on 1)

A treatment pack according to claim 1, comprising multiple containers, each of said multiple containers containing a single dose of said multiple doses.

### Claim 9

A composition comprising:
(a) a physiologically effective amount of dipyridamole formulated for treatment of the anterior segment of the eye of a subject suffering from an anterior segment eye disorder; and
(b) a physiologically acceptable carrier.

### Claim 10 (depends on 9)

A composition according to claim 9, formulated as a solution.

### Claim 11 (depends on 9)

A composition according to claim 9, formulated as a cream or ointment.

### Claim 12 (depends on 9)

A composition according to claim 9, wherein said physiologically effective amount of dipyridamole comprises a concentration of at least about 10−6 molar (moles/liter).

### Claim 13 (depends on 9)

A composition according to claim 9 comprising 200 μg/ml or less of dipyridamole.

### Claim 14 (depends on 13)

A composition according to claim 13, comprising 100 μg/ml or less of dipyridamole.

### Claim 15 (depends on 9)

A composition according to claim 9, not comprising a physiologically active concentration of any member of the group consisting of caffeine, a corticosteroid, a benzisoselenazole (e.g. ebselen), amoxapine, sertraline, dipivefrin, prostaglandin E, rolipram, an HDAC inhibitor, an additional anti-VEGF compound, and an HMG-CoA reductase inhibitor (e.g. a statin) and/or nitric oxide (NO) inhibitor.

### Claim 16

A method comprising:
(a) adjusting the pH of a physiologically acceptable ophthalmologic solution to between about 5.5 and about 6.8;
(b) dissolving dipyridamole in said solution at a concentration of 5 μg/ml to 200 μμg/ml; and
(c) sterilizing the resultant dipyridamole composition.

### Claim 17 (depends on 16)

A method according to claim 16, comprising titrating said solution to achieve said pH of about 6.7.

### Claim 18 (depends on 16)

A method according to claim 16, wherein said dissolving comprises dissolving at a concentration of at least 85 μg/ml.

### Claim 19 (depends on 16)

A method according to claim 16, comprising packaging the sterilized dipyridamole composition in container configured to deliver drops to the eye.

### Claim 20 (depends on 19)

A method according to claim 19, comprising assembling a treatment pack comprising said container, packaging material and instructions for topical administration of said composition to the eye to treat an anterior segment eye disorder in a subject in need thereof.
